{'fraction_non_alphanumeric': 0.03046594982078853, 'fraction_numerical': 0.014336917562724014, 'mean_word_length': 5.817073170731708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model

Purpose:  To test the efficacy of the novel candidate anticonvulsant talampanel (GYKI 53773) in a rodent model of hypoxic neonatal seizures. Talampanel is a noncompetitive antagonist of the alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid subtype of the glutamate receptor (AMPAR). We have previously shown that AMPARs play a critical role in the generation of acute seizures and later‐life seizure susceptibility in this model of neonatal seizures.